251 related articles for article (PubMed ID: 34537409)
21. SARS-CoV-2 M
Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
[TBL] [Abstract][Full Text] [Related]
22. Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An
Behera SK; Mahapatra N; Tripathy CS; Pati S
Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):132-143. PubMed ID: 33818470
[TBL] [Abstract][Full Text] [Related]
23. Searching for potential drugs against SARS-CoV-2 through virtual screening on several molecular targets.
Almeida JSFD; Botelho FD; de Souza FR; Dos Santos MC; Goncalves ADS; Rodrigues RLB; Cardozo M; Kitagawa DAS; Vieira LA; Silva RSF; Cavalcante SFA; Bastos LDC; Nogueira MOT; de Santana PIR; Brum JOC; Nepovimova E; Kuca K; LaPlante SR; Galante EBF; Franca TCC
J Biomol Struct Dyn; 2022 Jul; 40(11):5229-5242. PubMed ID: 33416020
[TBL] [Abstract][Full Text] [Related]
24. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
[TBL] [Abstract][Full Text] [Related]
25. Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study.
Vijayan V; Pant P; Vikram N; Kaur P; Singh TP; Sharma S; Sharma P
J Biomol Struct Dyn; 2021 Oct; 39(17):6713-6727. PubMed ID: 32741322
[TBL] [Abstract][Full Text] [Related]
26. Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations.
Kumar V; Liu H; Wu C
Comput Biol Med; 2021 Aug; 135():104634. PubMed ID: 34256255
[TBL] [Abstract][Full Text] [Related]
27. Target identification for repurposed drugs active against SARS-CoV-2 via high-throughput inverse docking.
Ribone SR; Paz SA; Abrams CF; Villarreal MA
J Comput Aided Mol Des; 2022 Jan; 36(1):25-37. PubMed ID: 34825285
[TBL] [Abstract][Full Text] [Related]
28. Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing.
Mosharaf MP; Reza MS; Kibria MK; Ahmed FF; Kabir MH; Hasan S; Mollah MNH
Sci Rep; 2022 Mar; 12(1):4279. PubMed ID: 35277538
[TBL] [Abstract][Full Text] [Related]
29. Computational drug repurposing study of antiviral drugs against main protease, RNA polymerase, and spike proteins of SARS-CoV-2 using molecular docking method.
Jalalvand A; Khatouni SB; Najafi ZB; Fatahinia F; Ismailzadeh N; Farahmand B
J Basic Clin Physiol Pharmacol; 2021 Jul; 33(1):85-95. PubMed ID: 34265888
[TBL] [Abstract][Full Text] [Related]
30. Identification of phytocompounds from Houttuynia cordata Thunb. as potential inhibitors for SARS-CoV-2 replication proteins through GC-MS/LC-MS characterization, molecular docking and molecular dynamics simulation.
Das SK; Mahanta S; Tanti B; Tag H; Hui PK
Mol Divers; 2022 Feb; 26(1):365-388. PubMed ID: 33961167
[TBL] [Abstract][Full Text] [Related]
31. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.
de Oliveira OV; Rocha GB; Paluch AS; Costa LT
J Biomol Struct Dyn; 2021 Jul; 39(11):3924-3933. PubMed ID: 32448085
[TBL] [Abstract][Full Text] [Related]
32.
Gurung AB
Gene Rep; 2020 Dec; 21():100860. PubMed ID: 32875166
[TBL] [Abstract][Full Text] [Related]
33. Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies.
Kutkat O; Moatasim Y; Al-Karmalawy AA; Abulkhair HS; Gomaa MR; El-Taweel AN; Abo Shama NM; GabAllah M; Mahmoud DB; Kayali G; Ali MA; Kandeil A; Mostafa A
Sci Rep; 2022 Jul; 12(1):12920. PubMed ID: 35902647
[TBL] [Abstract][Full Text] [Related]
34. Virtual screening FDA approved drugs against multiple targets of SARS-CoV-2.
Liang H; Zhao L; Gong X; Hu M; Wang H
Clin Transl Sci; 2021 May; 14(3):1123-1132. PubMed ID: 33606912
[TBL] [Abstract][Full Text] [Related]
35. Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants.
Yin J; Li C; Ye C; Ruan Z; Liang Y; Li Y; Wu J; Luo Z
Comput Struct Biotechnol J; 2022; 20():824-837. PubMed ID: 35126885
[TBL] [Abstract][Full Text] [Related]
36. Potential Candidates against COVID-19 Targeting RNA-Dependent RNA Polymerase: A Comprehensive Review.
Agrawal N; Goyal A
Curr Pharm Biotechnol; 2022; 23(3):396-419. PubMed ID: 33882805
[TBL] [Abstract][Full Text] [Related]
37. Enfuvirtide, an HIV-1 fusion inhibitor peptide, can act as a potent SARS-CoV-2 fusion inhibitor: an
Ahmadi K; Farasat A; Rostamian M; Johari B; Madanchi H
J Biomol Struct Dyn; 2022 Aug; 40(12):5566-5576. PubMed ID: 33438525
[TBL] [Abstract][Full Text] [Related]
38. Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs.
Farhat N; Khan AU
J Mol Model; 2021 Oct; 27(11):312. PubMed ID: 34601658
[TBL] [Abstract][Full Text] [Related]
39. Facilitating SARS CoV-2 RNA-Dependent RNA polymerase (RdRp) drug discovery by the aid of HCV NS5B palm subdomain binders: In silico approaches and benchmarking.
Elghoneimy LK; Ismail MI; Boeckler FM; Azzazy HME; Ibrahim TM
Comput Biol Med; 2021 Jul; 134():104468. PubMed ID: 34015671
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an
Elfiky AA
J Biomol Struct Dyn; 2021 Jun; 39(9):3204-3212. PubMed ID: 32338164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
